Editas Medicine (EDIT) Stock Analysis & AI Equity Report

Medical - Pharmaceuticals USD Explore free reports

Editas Medicine (EDIT) overview

Editas Medicine (EDIT) stock analysis and AI equity research. For financial year 2025, Valuatum's model shows revenue of USD 40.5m and operating profit of USD -160m; the year-end share price was 2.05 USD and market capitalisation was USD 201m. Editas Medicine is covered by Valuatum but does not yet have a published AI equity report. Generate a fresh report to get Editas Medicine's valuation, segment value analysis, reverse valuation, financial forecasts, key ratios, risks and catalysts.

Key metrics & valuation multiples

Book valueUSD 27.3mFY 2025
Share price2.05 USDFY 2025 year end
RevenueUSD 40.5mFY 2025
Operating profitUSD -160mFY 2025
Net earningsUSD -160mFY 2025
Market capitalisationUSD 201mFY 2025 year end

About Editas Medicine

Editas Medicine develops genomic medicines using CRISPR gene-editing technology. Its platform includes CRISPR/Cas9 and CRISPR/Cas12a systems used to create molecules designed to edit specific DNA sequences. Research focuses on in vivo gene editing, including approaches intended to increase expression of normal genes, and on lipid nanoparticle delivery methods. Programs target elevated LDL cholesterol and inherited blood disorders.

Generate the Editas Medicine report

Editas Medicine is on Valuatum's coverage list, but a full AI equity report hasn't been generated yet. Order one now for the complete company value map, reverse valuation, risk & catalyst analysis, and financial statements and estimates — plus a downloadable PDF.

Generate fresh report — €50.00 Delivered by email, usually within an hour

Sources & methodology

Financial figures are sourced from Valuatum's financial model for Editas Medicine and represent financial year 2025. See the methodology for the full Valuatum AI equity research framework.

Disclaimer: This is an AI-generated research material for informational purposes only. It is not investment advice or a buy/sell recommendation. Always perform your own analysis. Valuatum Oy, Helsinki, Finland.

Analyst reports on Editas Medicine

Each report here is this company's Valuatum report re-run with an analyst's own assumptions and published under their name. They are ordered by a score out of five: what other analysts felt the work added over the engine's default report.